SG11201810915QA - Preparation of factor xa derivatives - Google Patents
Preparation of factor xa derivativesInfo
- Publication number
- SG11201810915QA SG11201810915QA SG11201810915QA SG11201810915QA SG11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- suite
- south san
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351841P | 2016-06-17 | 2016-06-17 | |
| PCT/US2017/038169 WO2017219034A2 (en) | 2016-06-17 | 2017-06-19 | Preparation of factor xa derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810915QA true SG11201810915QA (en) | 2019-01-30 |
Family
ID=60663351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810915QA SG11201810915QA (en) | 2016-06-17 | 2017-06-19 | Preparation of factor xa derivatives |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10604748B2 (https=) |
| EP (3) | EP4588932A3 (https=) |
| JP (4) | JP6959268B2 (https=) |
| KR (1) | KR102373215B1 (https=) |
| CN (3) | CN118271391A (https=) |
| AU (2) | AU2017283720C1 (https=) |
| CL (2) | CL2018003654A1 (https=) |
| CO (1) | CO2019000120A2 (https=) |
| DK (1) | DK3472314T3 (https=) |
| EA (1) | EA037815B1 (https=) |
| ES (2) | ES2875538T3 (https=) |
| HU (1) | HUE054597T2 (https=) |
| IL (1) | IL263591B2 (https=) |
| MX (1) | MX2018015873A (https=) |
| PE (1) | PE20190661A1 (https=) |
| PH (1) | PH12018502614A1 (https=) |
| PL (1) | PL3472314T3 (https=) |
| PT (1) | PT3472314T (https=) |
| SG (1) | SG11201810915QA (https=) |
| SI (1) | SI3472314T1 (https=) |
| WO (1) | WO2017219034A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3121271B1 (en) * | 2009-03-30 | 2019-07-24 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| CA2898975C (en) * | 2013-01-24 | 2021-06-15 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
| PT3472314T (pt) * | 2016-06-17 | 2021-06-18 | Alexion Pharma Inc | Preparação de derivados do fator xa |
| JP2021527435A (ja) | 2018-06-19 | 2021-10-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤に対する解毒剤 |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189019A (en) * | 1990-04-23 | 1993-02-23 | Merck & Co., Inc. | Antistasin derived anticoagulant protein |
| US5589571A (en) | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| JPH1066572A (ja) * | 1996-08-29 | 1998-03-10 | Showa Sangyo Co Ltd | 高純度の大豆トリプシンインヒビターの製造方法 |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| PE20070717A1 (es) | 2005-11-08 | 2007-08-17 | Millennium Pharm Inc | Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida |
| EP2915564B1 (en) | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
| MX2011004907A (es) | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre. |
| EP3121271B1 (en) * | 2009-03-30 | 2019-07-24 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| ES2605801T3 (es) | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia |
| JP6261093B2 (ja) * | 2012-06-14 | 2018-01-17 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 組み換え第Ｘａ因子誘導体の精製のための方法 |
| US20140346397A1 (en) * | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| CA2898975C (en) * | 2013-01-24 | 2021-06-15 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
| EP3049434A1 (en) * | 2013-09-24 | 2016-08-03 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
| EP3750556A1 (en) * | 2014-08-20 | 2020-12-16 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
| PT3472314T (pt) * | 2016-06-17 | 2021-06-18 | Alexion Pharma Inc | Preparação de derivados do fator xa |
-
2017
- 2017-06-19 PT PT178142675T patent/PT3472314T/pt unknown
- 2017-06-19 ES ES17814267T patent/ES2875538T3/es active Active
- 2017-06-19 EP EP25172582.6A patent/EP4588932A3/en active Pending
- 2017-06-19 SG SG11201810915QA patent/SG11201810915QA/en unknown
- 2017-06-19 CN CN202410192888.7A patent/CN118271391A/zh active Pending
- 2017-06-19 WO PCT/US2017/038169 patent/WO2017219034A2/en not_active Ceased
- 2017-06-19 KR KR1020197000840A patent/KR102373215B1/ko active Active
- 2017-06-19 IL IL263591A patent/IL263591B2/en unknown
- 2017-06-19 EA EA201990052A patent/EA037815B1/ru not_active IP Right Cessation
- 2017-06-19 DK DK17814267.5T patent/DK3472314T3/da active
- 2017-06-19 JP JP2018565888A patent/JP6959268B2/ja active Active
- 2017-06-19 EP EP17814267.5A patent/EP3472314B1/en active Active
- 2017-06-19 EP EP21164923.1A patent/EP3926044B1/en active Active
- 2017-06-19 SI SI201730865T patent/SI3472314T1/sl unknown
- 2017-06-19 US US15/626,813 patent/US10604748B2/en active Active
- 2017-06-19 CN CN202310427500.2A patent/CN116425860B/zh active Active
- 2017-06-19 PE PE2018003241A patent/PE20190661A1/es unknown
- 2017-06-19 CN CN201780041530.2A patent/CN110167575B/zh active Active
- 2017-06-19 MX MX2018015873A patent/MX2018015873A/es unknown
- 2017-06-19 PL PL17814267T patent/PL3472314T3/pl unknown
- 2017-06-19 HU HUE17814267A patent/HUE054597T2/hu unknown
- 2017-06-19 ES ES21164923T patent/ES3038834T3/es active Active
- 2017-06-19 AU AU2017283720A patent/AU2017283720C1/en active Active
-
2018
- 2018-12-11 PH PH12018502614A patent/PH12018502614A1/en unknown
- 2018-12-17 CL CL2018003654A patent/CL2018003654A1/es unknown
-
2019
- 2019-01-09 CO CONC2019/0000120A patent/CO2019000120A2/es unknown
-
2020
- 2020-01-10 US US16/740,001 patent/US10954504B2/en active Active
- 2020-06-25 CL CL2020001733A patent/CL2020001733A1/es unknown
-
2021
- 2021-03-09 US US17/196,172 patent/US11845966B2/en active Active
- 2021-10-07 JP JP2021165271A patent/JP7273918B2/ja active Active
-
2023
- 2023-02-14 AU AU2023200825A patent/AU2023200825B2/en active Active
- 2023-04-28 JP JP2023074627A patent/JP2023086970A/ja active Pending
- 2023-11-08 US US18/505,022 patent/US20240076642A1/en active Pending
-
2025
- 2025-10-02 JP JP2025166337A patent/JP2026010692A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| SG11201810915QA (en) | Preparation of factor xa derivatives | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201806302RA (en) | Inhibitors of receptor-interacting protein kinase 1 | |
| SG11201806190TA (en) | Isotachophoresis for purification of nucleic acids | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810777WA (en) | Purification of multispecific antibodies | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201407662WA (en) | Process for the preparation of treprostinil and derivatives thereof | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201907764PA (en) | Methods for screening infections | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders |